Login / Signup

Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503).

Gretchen G KimmickBrittny MajorJonathan ClappJeff SloanBrandelyn PitcherKarla BallmanMyra BarginearRachel A FreedmanAndrew ArtzHeidi D KlepinJacqueline M LafkyJudith HopkinsEric WinerClifford HudisHyman MussHarvey CohenAminah JatoiArti HurriaJeanne Mandelblatt
Published in: Breast cancer research and treatment (2017)
ePrognosis tool only modestly overestimates mortality rate in older breast cancer patients enrolled in two cooperative group studies. This tool, which estimates non-cancer mortality risk based on readily available clinical information may inform adjuvant therapy decisions but should be validated in non-clinical trial populations.
Keyphrases
  • papillary thyroid
  • clinical trial
  • squamous cell
  • physical activity
  • community dwelling
  • middle aged
  • bone marrow
  • type diabetes
  • cardiovascular events
  • randomized controlled trial
  • healthcare
  • open label
  • phase ii